# Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

> **NCT01447394** · PHASE3 · WITHDRAWN · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Hepatitis C Virus (HCV)

## Interventions

- **BIOLOGICAL:** Pegylated Interferon Lambda
- **BIOLOGICAL:** Pegylated Interferon Alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01447394
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-03
- **Primary completion:** 2014-03
- **Final completion:** 2014-08
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01447394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01447394, "Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01447394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*